Related references
Note: Only part of the references are listed.A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
F. A. L. M. Eskens et al.
BRITISH JOURNAL OF CANCER (2014)
Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors
Cristiana Sessa et al.
CLINICAL CANCER RESEARCH (2013)
The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models
Celine Clemenson et al.
INVESTIGATIONAL NEW DRUGS (2013)
International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1
Giorgio V. Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer
M. Zweifel et al.
ANNALS OF ONCOLOGY (2011)
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non-Small-Cell Lung Cancer
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cardiovascular Toxicity Profiles of Vascular-Disrupting Agents
Ishwaria M. Subbiah et al.
ONCOLOGIST (2011)
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
A. du Bois et al.
ANNALS OF ONCOLOGY (2010)
Disrupting Established Tumor Blood Vessels An Emerging Therapeutic Strategy for Cancer
Mark J. McKeage et al.
CANCER (2010)
Carboplatin and Paclitaxel in Combination With Oral Enzastaurin in Advanced Ovarian or Primary Peritoneal Cancer Results From a Safety Lead-in Study
Ignace Vergote et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer
Vernon Harvey et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors
A. Felici et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo
Y Morinaga et al.
CANCER SCIENCE (2003)
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs
K Hori et al.
BRITISH JOURNAL OF CANCER (2002)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
